S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ZVSA ZyVersa Therapeutics Inc

1.13

-0.02 (-1.74%)

Pre Market

Last Updated: 01:25:13

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Dec 2024 to Dec 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics Inc News

Form 424B3 - Prospectus [Rule 424(b)(3)]
Tuesday 31 December 2024 (1 hour ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Friday 27 December 2024 (3 days ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Saturday 21 December 2024 (1 week ago) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Saturday 21 December 2024 (1 week ago) • Edgar (US Regulatory)

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
Wednesday 18 December 2024 (2 weeks ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Wednesday 20 November 2024 (1 month ago) • GlobeNewswire Inc.

Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Saturday 16 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Friday 15 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

More ZyVersa Therapeutics Inc News Articles

Daily Mail6.375

Green Leaf Innovations (PK)

Bounce Mobile Systems (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions